Antipsychotic drugs and their possible cardiovascular adverse effects – literature review
DOI:
https://doi.org/10.12923/2353-8627/2024-0020Keywords:
antipsychotic medication, myocarditis, cardiotoxicity, cardiac arrhythmia, orthostatic hypotensionAbstract
Introduction: Antipsychotic medication, frequently prescribed for managing psychosis, significantly enhance the quality of life for psychiatric patients. Nonetheless, they also harbor the risk of triggering cardiovascular side effects, which can range in severity and may pose challenges for patients, potentially disrupting their therapy. This study aims to elucidate these adverse effects, their potential etiology, and their prevalence.
Material and methods: A review of available literature was performed by searching PubMed and Google Scholar, using the following keywords: antipsychotic drugs, adverse effects, cardiotoxicity, arrhythmia for original papers, review papers and meta-analyses published from 1992 to 2024.
Discussion: It has been well-known for a long time that antipsychotic medication carries a lot of possible adverse effects. The cardiovascular adverse effects associated with antipsychotic medication encompass orthostatic hypotension, prolongation of the QT interval, atrial fibrillation, alterations in heart rate and cardiotoxicity, which may include myocarditis and cardiomyopathy. Fortunately, the occurrence of the most severe complications stemming from these effects is relatively uncommon. While the adverse effects of first and second-generation antipsychotics are extensively documented, further research is warranted to investigate the potential side effects of third-generation antipsychotic drugs.
Conclusions: Cardiovascular adverse effects associated with antipsychotics can pose significant challenges and may even be life-threatening for patients. However, awareness of these effects should not discourage clinicians from prescribing them. Instead, it should motivate them to deepen their understanding and expertise. It would definitely lead to the improvement of patient care and treatment outcomes.
References
1. Benistand P, Vorilhon P, Bouillon-Minois JB, Brousse G, Baker JS, Flaudias V, Mulliez A, Dutheil F. Effect of the COVID-19 pandemic on the psychotropic drug consumption. Frontiers in Psychiatry. 2022 Dec 15;13:1020023.
2. Ministerstwo Zdrowia [Internet]. [cited 2024 Aug 08];Available from: https://archiwum.mz.gov.pl/zdrowie-i-profilaktyka/ promoc ja-zdrowia/jakdzialazdrowyczlowiek/zdrowie¬psychiczne-polakow-w-roli-glownej-mozg/
3. Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, Il Shin J, Kirkbride JB, Jones P, Kim JH, Kim JY. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Molecular psychiatry. 2022 Jan;27(1):281-95.
4. Ayano G. Schizophrenia: a concise overview of etiology, epidemiology diagnosis and management: review of literatures. J Schizophrenia Res. 2016 Aug;3(2):2-7.
5. Chen Q, Huang S, Xu H, Peng J, Wang P, Li S, Zhao J, Shi X, Zhang W, Shi L, Peng Y. The burden of mental disorders in Asian countries, 1990–2019: An analysis for the global burden of disease study 2019. Translational Psychiatry. 2024 Mar 28;14(1):167.
6. Read J, Williams J. Positive and negative effects of antipsychotic medication: an international online survey of 832 recipients. Current Drug Safety. 2019 Nov 1;14(3):173-81.
7. Carmona-Huerta J, Castiello-de Obeso S, Ramírez-Palomino J, Duran-Gutiérrez R, Cardona-Muller D, Grover-Paez F, Fernández-Dorantes P, Medina-Dávalos R. Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC psychiatry. 2019 Dec;19:1-0.
8. González-Rodríguez A, Monreal JA, Natividad M, Seeman MV. Seventy years of treating delusional disorder with antipsychotics: A historical perspective. Biomedicines. 2022 Dec 18;10(12):3281.
9. Stahl S. M. Essential Psychofarmacology. Cambridge; Cambridge University Press: 2000
10. Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, McCormick PJ, Corsini GU, Maggio R, Scarselli M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacology & Therapeutics. 2018 Dec 1;192:20-41.
11. Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS drugs. 2022 Jul;36(7):659-79.
12. Ricci V, De Berardis D, Maina G. Third-generation antipsychotics and lurasidone in the treatment of substance-induced psychoses: A narrative review. InHealthcare 2024 Jan 29 (Vol. 12, No. 3, p. 339). MDPI.
13. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G. An update of safety of clinically used atypical antipsychotics. Expert opinion on drug safety. 2016 Oct 2;15(10):1329-47.
14. Destere A, Merino D, Lavrut T, Rocher F, Viard D, Drici MD, Gérard AO. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review. Therapies. 2023 Oct 31.
15. Sun D, Li L, Zhang X, Blanchard TG, Fowler DR, Li L. Causes of sudden unexpected death in schizophrenia patients: a forensic autopsy population study. The American Journal of Forensic Medicine and Pathology. 2019 Dec 1;40(4):312-7.
16. Kanniah G, Kumar S. Clozapine associated cardiotoxicity: issues, challenges and way forward. Asian Journal of Psychiatry. 2020 Apr 1;50:101950.
17. Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS chemical neuroscience. 2014 Jan 15;5(1):24-9.
18. Masdrakis VG, Baldwin DS. Prevention of suicide by clozapine in mental disorders: systematic review. European Neuropsychopharmacology. 2023 Apr 1;69:4-23.
19. Mackin P. Cardiac side effects of psychiatric drugs. Human Psychopharmacology: Clinical and Experimental. 2008 Jan;23(S1):S3-14.
20. Wieling W, Kaufmann H, Claydon VE, van Wijnen VK, Harms MP, Juraschek SP, Thijs RD. Diagnosis and treatment of orthostatic hypotension. The Lancet Neurology. 2022 Aug 1;21(8):735-46.
21. Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiology research and practice. 2014 Feb 4;2014.
22. Cahaya N, Wijaya SP, Anwar K. Incidence of Orthostatic Hypotension in Schizophrenic Patients Using Antipsychotics at Sambang Lihum Mental Health Hospital, South Kalimantan. Borneo Journal of Pharmacy. 2021 Aug 30;4(3):210-8.
23. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS drugs. 2011 Aug;25:659-71.
24. Li XQ, Tang XR, Li LL. Antipsychotics cardiotoxicity: what's known and what's next. World Journal of Psychiatry. 2021 Oct 10;11(10):736.
25. Khatib R, Sabir FR, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgraduate medical journal. 2021 Jul;97(1149):452-8.
26. Curtis LH, Ostbye T, Sendersky V, Hutchison S, LaPointe NM, Al-Khatib SM, Yasuda SU, Dans PE, Wright A, Califf RM, Woosley RL. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. The American journal of medicine. 2003 Feb 1;114(2):135-41.
27. Niimi N, Yuki K, Zaleski K. Long QT syndrome and perioperative torsades de pointes: what the anesthesiologist should know. Journal of Cardiothoracic and Vascular Anesthesia. 2022 Jan 1;36(1):286-302.
28. Yeung C, Baranchuk A. Overview of torsades de pointes. InTorsades de Pointes 2022 Jan 1 (pp. 1-26). Academic Press.
29. Sweeney M, Whiskey E, Patel RK, Tracy DK, Shergill SS, Plymen CM. Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia. BJPsych Advances. 2020 Jan;26(1):26-40.
30. Stollings JL, Boncyk CS, Birdrow CI, Chen W, Raman R, Gupta DK, Roden DM, Rivera EL, Maiga AW, Rakhit S, Pandharipande PP. Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open. 2024 Jan 2;7(1):e2352034-.
31. Hommers L, Scherf-Clavel M, Stempel R, Roth J, Falter M, Deckert J, Mattheisen M, Unterecker S, Gawlik M. Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. Journal of Psychopharmacology. 2021 Sep;35(9):1127-33.
32. Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J, Videbech P, Pehrson S, Bundgaard H. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European heart journal. 2014 May 21;35(20):1306-15.
33. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC: Clinical Electrophysiology. 2017 May;3(5):425-35.
34. Katsanos AH, Kamel H, Healey JS, Hart RG. Stroke prevention in atrial fibrillation: looking forward. Circulation. 2020 Dec 15;142(24):2371-88.
35. Tamargo J, Villacastín J, Caballero R, Delpón E. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect. Pharmacological Research. 2024 Jan 19:107077.
36. Chou RH, Lo LW, Liou YJ, Shu JH, Hsu HC, Liang Y, Huang CC, Huang PH, Lin SJ, Chen JW, Chan WL. Antipsychotic treatment is associated with risk of atrial fibrillation: a nationwide nested case-control study. International journal of cardiology. 2017 Jan 15;227:134-40.
37. Tamargo J, Caballero R, Delpon E. Drug-induced atrial fibrillation. Expert opinion on drug safety. 2012 Jul 1;11(4):615¬34.
38. Yaylaci S, Tamer A, Kocayigit I, Gunduz H. Atrial fibrillation due to olanzapine overdose. Clinical Toxicology. 2011 Jun 1;49(5):440-.
39. ÇAM B, GÜLSEREN L, METE L, GÜLSEREN Ş. Atrial Fibrillation Associated with Clozapine and Olanzapine: A Case Report. Turkish Journal of Psychiatry. 2015 Sep 1;26(3).
40. Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. American Journal of Health-System Pharmacy. 2008 Nov 15;65(22):2122-5.
41. Lim AK, Azraai M, Pham JH, Looi WF, Wirth D, Ng AS, Babu U, Saluja B. Severe tachycardia associated with psychotropic medications in psychiatric inpatients: a study of hospital medical emergency team activation. Journal of Clinical Medicine. 2021 Apr 6;10(7):1534.
42. Lally J, Docherty MJ, MacCabe JH. Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database of Systematic Reviews. 2016(6).
43. Sharma N, Bhat S, Ravi D, Ochieng P. Severe hypothermia, bradycardia and cardiac arrest in association with risperidone. BMJ Case Reports CP. 2020 May 1;13(5):e234999.
44. Nakamura M, Seki M, Sato Y, Nagamine T. Quetiapine-induced bradycardia and hypotension in the elderly—a case report. Innovations in clinical neuroscience. 2016 Jan;13(1-2):34.
45. Huang LC, Huang LY, Tseng SY, Hou YM, Hsiao CC. Amisulpride and symptomatic bradycardia: a case report. General hospital psychiatry. 2015 Sep 1;37(5):497-e1.
46. Huhn M, Arndt T, Schneider-Thoma J, Leucht S. Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2022 Jun;12:20451253221097261.
47. Ronaldson KJ. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS drugs. 2017 Sep;31(9):777-95.
48. Varambally S, Howpage P. Acute myocarditis associated with clozapine. Australasian Psychiatry. 2007 Aug;15(4):343-6.
49. Vickers M, Ramineni V, Malacova E, Eriksson L, McMahon K, Moudgil V, Scott J, Siskind D. Risk factors for clozapine¬induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2022 May;145(5):442-55.
50. Daniel P, Rajaree KM, Rudy L, Jafor S, Prasad S, Avanthika C, Jhaveri S. Myocarditis in patients on long-term antipsychotics– mechanism, management and recent updates. Heliyon. 2023 Mar 1;9(3).
51. Halawa N, Armstrong M, Fancy S, Abidi S. Clozapine-induced myocarditis and subsequent rechallenge: A narrative literature review and case report. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2023 Nov;32(4):e252.
52. Bellissima BL, Burns KE, Helsby NA, Kingston EL, Garavan F, Tingle MD. Clozapine metabolism and cardiotoxicity: A prospective longitudinal study. International Journal of Cardiology. 2024 Jan 18:131788.
53. Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis. International journal of cardiology. 2018 May 15;259:122-9.
54. Wassef N, Khan N, Munir S. Quetiapine-induced myocarditis presenting as acute STEMI. Case Reports. 2015 Jan 9;2015:bcr2014207151.
55. Vang T, Rosenzweig M, Bruhn CH, Polcwiartek C, Kanters JK, Nielsen J. Eosinophilic myocarditis during treatment with olanzapine-report of two possible cases. BMC psychiatry. 2016 Dec;16:1-4.
56. De Las Cuevas C, Sanz EJ, Rohde C, de Leon J. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Review of Clinical Pharmacology. 2022 Jan 2;15(1):65-78.
57. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australasian psychiatry. 2016 Apr;24(2):176-80.
58. Brieler JA, Breeden MA, Tucker J. Cardiomyopathy: an overview. American family physician. 2017 Nov 15;96(10):640-6.
59. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. The Lancet. 2017 Jul 22;390(10092):400-14.
60. Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, Kisely S. Systematic review and meta-analysis of rates of clozapine¬associated myocarditis and cardiomyopathy. Australian & New Zealand Journal of Psychiatry. 2020 May;54(5):467-81.
61. Knoph KN, Morgan III RJ, Palmer BA, Schak KM, Owen AC, Leloux MR, Patel M, Leung JG. Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophrenia research. 2018 Sep 1;199:17-30.
62. Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014. Psychopharmacology. 2018 Jul;235:1915-21.
63. Curto M, Girardi N, Lionetto L, Ciavarella GM, Ferracuti S, Baldessarini RJ. Systematic review of clozapine cardiotoxicity. Current Psychiatry Reports. 2016 Jul;18:1-8.
64. Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL, French Association of Regional PharmacoVigilance Centres. Drugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance Database. British journal of clinical pharmacology. 2010 Mar;69(3):287-94.
65. Smolders DM, Smolders WA. Case report and review of the literature: cardiomyopathy in a young woman on high-dose quetiapine. Cardiovascular Toxicology. 2017 Oct;17:478-81.
66. Whiskey E, Yuen S, Khosla E, Piper S, O’Flynn D, Taylor D. Resolution without discontinuation: heart failure during clozapine treatment. Therapeutic Advances in Psychopharmacology. 2020 Jun;10:2045125320924786.
67. Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. Expert opinion on drug safety. 2016 May 3;15(5):679-88.
68. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. Journal of the American College of Cardiology. 1992 Nov 15;20(6):1391-6.
69. Coppola G, Corrado E, Curnis A, Maglia G, Oriente D, Mignano A, Brugada P. Update on Brugada syndrome 2019. Current problems in cardiology. 2021 Mar 1;46(3):100454.
70. Yuan M, Tian C, Li X, Yang X, Wang X, Yang Y, Liu N, Kusano KF, Barajas-Martinez H, Hu D, Shang H. Gender differences in prognosis and risk stratification of Brugada syndrome: a pooled analysis of 4,140 patients from 24 clinical trials. Frontiers in Physiology. 2018 Aug 22;9:398412.
71. Sicouri S, Antzelevitch C. Mechanisms underlying the actions of antidepressant and antipsychotic drugs that cause sudden cardiac arrest. Arrhythmia & electrophysiology review. 2018 Aug;7(3):199.
72. Handley SA, Every-Palmer S, Flanagan RJ. Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019: The Impact of Second-Generation Antipsychotics. Journal of clinical psychopharmacology. 2021 Nov 1;41(6):650-7.
73. Siafis S, Schneider-Thoma J, Hamza T, Bighelli I, Dong S, Hansen WP, Davis JM, Salanti G, Leucht S. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ open. 2023 Feb 1;13(2):e064504.
74. Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. British medical bulletin. 2020 Sep;135(1):73-89.
75. Wagner E, Siskind D, Falkai P, Howes O, Correll C, Lee J, Honer WG, Kane JM, Fernandez-Egea E, Barnes TR, Hasan A. Clozapine optimization: a delphi consensus guideline from the treatment response and resistance in psychosis working group. Schizophrenia bulletin. 2023 Jul 1;49(4):962-72.
76. Mar PL, Horbal P, Chung MK, Dukes JW, Ezekowitz M, Lakkireddy D, Lip GY, Miletello M, Noseworthy PA, Reiffel JA, Tisdale JE. Drug interactions affecting antiarrhythmic drug use. Circulation: Arrhythmia and Electrophysiology. 2022 May;15(5):e007955.
77. Castaldelli-Maia JM, Hofmann C, Chagas AC, Liprandi AS, Alcocer A, Andrade LH, Wielgosz A. Major cardiac–psychiatric drug–drug interactions: a systematic review of the consistency of drug databases. Cardiovascular Drugs and Therapy. 2021 Jun;35:441-54.
78. Das B, Ramasubbu SK, Agnihotri A, Kumar B, Rawat VS. Leading 20 drug–drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. Therapeutic Advances in Cardiovascular Disease. 2021 Nov;15:17539447211058892.
79. Morishita H, Perera LM, Sunakawa H, Kimura S, Yoshida H, Ogihara T. P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database. The Journal of Clinical Pharmacology. 2024 Jan;64(1):118-24.
80. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology. 2021 Feb;238:329-40.
81. Blasco-Fontecilla H, Baca-Garcia E, de Leon J. Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade. Schizophrenia research. 2010 Jun 1;119(1-3):160-3.
82. Maroteaux L, Kilic F. Frontiers of serotonin beyond the brain. Pharmacological research. 2019 Feb;140:1.
83. Rieder M, Gauchel N, Bode C, Duerschmied D. Serotonin: a platelet hormone modulating cardiovascular disease. Journal of thrombosis and thrombolysis. 2021 Jul;52(1):42-7.
84. Monassier L, Maroteaux L. Serotonin and cardiovascular diseases. Serotonin. 2019 Jan 1:203-38.
85. Spadaro A, Scott KR, Koyfman A, Long B. High risk and low prevalence diseases: Serotonin syndrome. The American Journal of Emergency Medicine. 2022 Nov 1;61:90-7.
86. Orsolini L, De Berardis D, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety. 2020 Aug 2;19(8):981-98.
87. Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The journal of clinical psychiatry. 2020 May 19;81(3):3649.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
